Bioasis Technologies

Bioasis Technologies Enterprise Value

The Enterprise Value (EV) of Bioasis Technologies (BIOAF) as of Oct 21, 2026 is 184,637.44 CAD. In the previous year, Enterprise Value (EV) was -2.61 M CAD — a change of -107.08% (higher).

Enterprise Value

184,637.44CAD

YoY

-107.08%

Last updated:

Enterprise Value (EV) of Bioasis Technologies is 2022 184,637.44 CAD. Enterprise Value (EV) of Bioasis Technologies was 2021 -2.61 M CAD. It decreases by -107.08% higher compared to the previous year.

The Bioasis Technologies Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2015
-1.63 M CAD
Jan 1, 2016
-1.61 M CAD
Jan 1, 2017
-540,662.56 CAD
Jan 1, 2018
-664,362.56 CAD
Jan 1, 2019
-1.35 M CAD
Jan 1, 2020
440,837.44 CAD
Jan 1, 2021
-2.61 M CAD
Jan 1, 2022
184,637.44 CAD
The Bioasis Technologies Enterprise Value history
YEAREnterprise ValueYoY
184,637.44CAD-107.08%
-2.61 MCAD-691.96%
440,837.44CAD-132.74%
-1.35 MCAD+102.65%
-664,362.56CAD+22.88%
-540,662.56CAD-66.40%
-1.61 MCAD-1.06%
-1.63 MCAD-10.95%
-1.83 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

Enterprise Value (EV) of Bioasis Technologies is 184,637.44 CAD in 2022.

Enterprise Value (EV) of Bioasis Technologies changed from -2.61 M CAD to 184,637.44 CAD, representing a -107.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s CAD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' CAD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioasis Technologies

All Key Metrics — Bioasis Technologies